AB Science Participates in Biomed Forum Investors Conference

Paris-based pharmaceutical company, AB Science SA, confirmed its participation in the Biomed Forum for institutional investors. This event, organized by AllInvest Securities, is scheduled for February 4, 2025, in Paris.

AB Science specializes in research and development of protein kinase inhibitors (PKIs). These targeted proteins play a crucial role in cellular signaling pathways. The company's focus is on diseases with high unmet medical needs. Their lead compound, masitinib, is already registered for veterinary use and is under development for human applications in various medical fields, including oncology and neurology.

AB Science is publicly traded on Euronext Paris. The company prioritizes transparency in communicating their financial and operational strategies while recognizing the inherent risks in drug development and marketing authorizations.